Search Results - "Ramirez, Kristen Aufiero"

A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma by Postow, Michael A, Knox, Susan J, Goldman, Debra A, Elhanati, Yuval, Mavinkurve, Vikram, Wong, Phillip, Halpenny, Darragh, Reddy, Sunil K, Vado, Kenya, McCabe, Danielle, Ramirez, Kristen Aufiero, Macri, Mary, Schwarzenberger, Paul, Ricciardi, Toni, Ryan, Aileen, Venhaus, Ralph, Momtaz, Parisa, Shoushtari, Alexander N, Callahan, Margaret K, Chapman, Paul B, Wolchok, Jedd D, Subrahmanyam, Priyanka B, Maecker, Holden T, Panageas, Katherine S, Barker, Christopher A

“…Preclinical data suggest that radiotherapy (RT) is beneficial in combination with immune checkpoint blockade. Clinical trials have explored RT with…”
Get full text

Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma by Carroll, Thomas M., Chadwick, Joseph A., Owen, Richard P., White, Michael J., Kaplinsky, Joseph, Peneva, Iliana, Frangou, Anna, Xie, Phil F., Chang, Jaeho, Roth, Andrew, Amess, Bob, James, Sabrina A., Rei, Margarida, Fuchs, Hannah S., McCann, Katy J., Omiyale, Ayo O., Jacobs, Brittany-Amber, Lord, Simon R., Norris-Bulpitt, Stewart, Dobbie, Sam T., Griffiths, Lucinda, Ramirez, Kristen Aufiero, Ricciardi, Toni, Macri, Mary J., Ryan, Aileen, Venhaus, Ralph R., Van den Eynde, Benoit J., Karydis, Ioannis, Schuster-Böckler, Benjamin, Middleton, Mark R., Lu, Xin, Ahern, David, Amess, Bob, Ramirez, Kristen Aufiero, Berridge, Georgina, Carroll, Thomas M., Chadwick, Joseph A., Chang, Jaeho, Cheng, Jingfei, Dobbie, Sam T., Drozdz, Magdalena, Fischer, Roman, Frangou, Anna, Fuchs, Hannah S., Griffiths, Lucinda, Inoue, Masato, Jacobs, Brittany-Amber, James, Sabrina A., Kaplinsky, Joseph, Karydis, Ioannis, Kessler, Benedikt M., Lord, Simon R., Lou, Hantao, Lu, Xin, Macri, Mary J., McCann, Katy J., McGregor, Naomi, Middleton, Mark R., Norris-Bulpitt, Stewart, Omiyale, Ayo O., Owen, Richard P., Peneva, Iliana, Phetsouphanh, Chansavath, Rei, Margarida, Ricciardi, Toni, Roth, Andrew, Puig, Carlos Ruiz, Ryan, Aileen, Schuster-Böckler, Benjamin, Siejka-Zielińska, Paulina, Song, Chunxiao, Tomkova, Marketa, Van den Eynde, Benoit J., Velikova, Gergana, Venhaus, Ralph R., White, Michael J., Xie, Phil F.

“…For inoperable esophageal adenocarcinoma (EAC), identifying patients likely to benefit from recently approved immunochemotherapy (ICI+CTX) treatments remains a…”
Get full text

Phase 1/2 study of mRNA vaccine therapy + durvalumab (durva) ± tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC) by Gandhi, Leena, Aufiero Ramirez, Kristen, Schwarzenberger, Paul, Ricciardi, Toni, Macri, Mary J., Ryan, Aileen, Venhaus, Ralph Rudolph

“…Abstract only…”
Get full text

Abstract 1247: Comprehensive molecular profiling to predict first-line immunochemotherapy outcomes in inoperable esophageal adenocarcinoma by Carroll, Thomas M., Chadwick, Joseph A., Owen, Richard P., White, Michael J., Kaplinsky, Joseph, Peneva, Iliana, Frangou, Anna, Chang, Jaeho, Xie, Phil F., Roth, Andrew, Amess, Bob, Lou, Hantao, McCann, Katy J., Berridge, Georgina, Fischer, Roman, Phetsouphanh, Chansavath, Omiyale, Ayo O., Jacobs, Brittany-Amber, Ahern, David, Lord, Simon R., Norris-Bulpitt, Stewart, Dobbie, Sam T., Griffiths, Lucinda, Ramirez, Kristen Aufiero, Ricciardi, Toni, Macri, Mary J., Ryan, Aileen, Venhaus, Ralph R., Van den Eynde, Benoit J., Karydis, Ioannis, Kessler, Benedikt M., Schuster-Böckler, Benjamin, Middleton, Mark R., Lu, Xin

“…For patients with inoperable esophageal adenocarcinoma (EAC), prognosis on conventional chemotherapy (CTX) remains poor. In 2021, the FDA approved two αPD-1…”
Get full text